The CYP4A11 Gene: A Potential Drug Target for Obesity, Diabetes and Cardiovascular Diseases

Target Name: CYP4A11

NCBI ID: G1579

The CYP4A11 Gene: A Potential Drug Target for Obesity, Diabetes and Cardiovascular Diseases

CYP4A11 (fatty acid omega-hydroxylase), is a gene that encodes a protein located in the endoplasmic reticulum (ER) and it is involved in the synthesis of fatty acids from carbon sources such as fatty acids or modified fatty acids. This gene is a potential drug target or biomarker for several diseases, including obesity, diabetes, and cardiovascular diseases.

The CYP4A11 gene encodes a protein that is a key enzyme in the synthesis of fatty acids from carbon sources. It is a member of the CYP4A subfamily of the cytochrome P450 enzyme superfamily and is responsible for the conversion of fatty acids fromaromatic to alphabetic acids. This enzyme is found in various tissues throughout the body and is involved in the synthesis of a variety of compounds, including fatty acids, steroids, and other molecules that are important for cellular function and signaling.

One of the unique features of the CYP4A11 gene is its role in the synthesis of fatty acids from modified fatty acids. Modified fatty acids are often synthesized in response to changes in cellular signaling pathways and can have a range of functions, including modulating inflammation, improving insulin sensitivity, and contributing to the development of certain diseases. The CYP4A11 gene is involved in the synthesis of these modified fatty acids and is a potential drug target or biomarker for several diseases.

In addition to its role in the synthesis of modified fatty acids, the CYP4A11 gene is also involved in the regulation of cellular signaling pathways. It is a key regulator of the androgen signaling pathway, which is involved in the regulation of male sexual function and the development of certain diseases such as prostate cancer. The CYP4A11 gene is also involved in the regulation of the insulin signaling pathway, which is responsible for the regulation of cellular metabolism and is involved in the development of several diseases, including type 2 diabetes.

The CYP4A11 gene is also involved in the regulation of inflammation. It is a key regulator of the pro-inflammatory response and is involved in the development of several diseases, including obesity and cardiovascular diseases. The CYP4A11 gene is also involved in the regulation of cellular apoptosis, which is the process by which cells respond to environmental stressors and attempt to remove damaged or unnecessary cells. This process is important for maintaining cellular homeostasis and is involved in the development of several diseases, including cancer.

The CYP4A11 gene is also involved in the regulation of cellular signaling pathways that are involved in the development of diseases such as aging and neurodegeneration. The CYP4A11 gene is involved in the regulation of cellular signaling pathways that are involved in the development of diseases such as aging and neurodegeneration, including the regulation of cellular senescence, which is the process by which cells become less functional and are involved in the development of diseases such as Alzheimer's disease.

In conclusion, the CYP4A11 gene is a potential drug target or biomarker for several diseases, including obesity, diabetes, and cardiovascular diseases. Its role in the synthesis of fatty acids from carbon sources and its involvement in the regulation of cellular signaling pathways, including the androgen and insulin signaling pathways, as well as its involvement in the regulation of inflammation, cellular apoptosis, and cellular aging, make it a promising candidate for drug development. Further research is needed to fully understand the role of the CYP4A11 gene in diseases and to develop effective treatments.

Protein Name: Cytochrome P450 Family 4 Subfamily A Member 11

Functions: A cytochrome P450 monooxygenase involved in the metabolism of fatty acids and their oxygenated derivatives (oxylipins) (PubMed:7679927, PubMed:1739747, PubMed:8914854, PubMed:10553002, PubMed:10660572, PubMed:15611369). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (CPR; NADPH-ferrihemoprotein reductase) (PubMed:7679927, PubMed:1739747, PubMed:8914854, PubMed:10553002, PubMed:10660572, PubMed:15611369). Catalyzes predominantly the oxidation of the terminal carbon (omega-oxidation) of saturated and unsaturated fatty acids, the catalytic efficiency decreasing in the following order: dodecanoic > tetradecanoic > (9Z)-octadecenoic > (9Z,12Z)-octadecadienoic > hexadecanoic acid (PubMed:10553002, PubMed:10660572). Acts as a major omega-hydroxylase for dodecanoic (lauric) acid in liver (PubMed:7679927, PubMed:1739747, PubMed:8914854, PubMed:15611369). Participates in omega-hydroxylation of (5Z,8Z,11Z,14Z)-eicosatetraenoic acid (arachidonate) to 20-hydroxyeicosatetraenoic acid (20-HETE), a signaling molecule acting both as vasoconstrictive and natriuretic with overall effect on arterial blood pressure (PubMed:10620324, PubMed:10660572, PubMed:15611369). Can also catalyze the oxidation of the penultimate carbon (omega-1 oxidation) of fatty acids with lower efficiency (PubMed:7679927). May contribute to the degradation of saturated very long-chain fatty acids (VLCFAs) such as docosanoic acid, by catalyzing successive omega-oxidations to the corresponding dicarboxylic acid, thereby initiating chain shortening (PubMed:18182499). Omega-hydroxylates (9R,10S)-epoxy-octadecanoate stereoisomer (PubMed:15145985). Plays a minor role in omega-oxidation of long-chain 3-hydroxy fatty acids (PubMed:18065749). Has little activity toward prostaglandins A1 and E1 (PubMed:7679927)

More Common Targets